|
FOLFOX4 survival (PFS and OS)
|
100%
|
80–120%
|
20%
|
Normal
|
|
Sorafenib survival (PFS and OS)
|
100%
|
80–120%
|
20%
|
Normal
|
|
Sorafenib monthly cost
|
3777
|
3021–4532
|
1126
|
Gamma
|
|
FOLFOX4 monthly cost
|
1865
|
1492–2238
|
373
|
Gamma
|
|
Dosage per cycle Oxaliplatin
|
138
|
110–166
|
28
|
Normal
|
|
Dosage per cycle 5-FU
|
3247
|
2597–3896
|
649
|
Normal
|
|
Dosage per cycle L-FC
|
649
|
519–779
|
130
|
Normal
|
|
Utility PFS
|
0.76
|
0.61–0.91
|
0.152
|
Normal
|
|
Utility PD
|
0.68
|
0.54–0.82
|
0.136
|
Normal
|
|
General ward cost per cycle
|
39
|
19–78
|
8
|
Gamma
|
|
AE costs
|
100%
|
50/200%
|
20%
|
Gamma
|
|
Cost of HCC progression test (RMB)
|
155
|
78–310
|
93
|
Gamma
|
|
Proportion of FOLFOX4 general ward
|
100%
|
50%
|
N/A
|
N/A
|
|
Discount rate
|
5%
|
0–8%
|
N/A
|
N/A
|
